Fig. 6From: Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysisRanking plot based on the probabilities of interventions in the analysis of secondary outcomes. PFS (A), OS (B), and severe AEs based on different endocrine therapies including AI (C) and fulvestrant (D). Treatments are ranked according to their chance of being the best treatment, and the height of each column reflects the probability of the rankBack to article page